Experimental Induction of Fluconazole Resistance in Candida tropicalis ATCC 750
- 1 June 2000
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 44 (6) , 1578-1584
- https://doi.org/10.1128/aac.44.6.1578-1584.2000
Abstract
Candida tropicalis is less commonly isolated from clinical specimens than Candida albicans. UnlikeC. albicans, which can be occasionally found as a commensal, C. tropicalis is almost always associated with the development of fungal infections. In addition, C. tropicalis has been reported to be resistant to fluconazole (FLC). To analyze the development of FLC resistance in C. tropicalis, an FLC-susceptible strain (ATCC 750) (MIC = 1.0 μg/ml) was cultured in liquid medium containing increasing FLC concentrations from 8.0 to 128 μg/ml. The strain developed variable degrees of FLC resistance which paralleled the concentrations of FLC used in the medium. The highest MICs of FLC were 16, 256, and 512 μg/ml for strains grown in medium with 8.0, 32, and 128 μg of FLC per ml, respectively. Development of resistance was rapid and could be observed already after a single subculture in azole-containing medium. The resistant strains were cross-resistant to itraconazole (MIC > 1.0 μg/ml) and terbinafine (MIC > 512 μg/ml) but not to amphotericin B. Isolates grown in FLC at concentrations of 8.0 and 32 μg/ml reverted to low MICs (1.0 μg/ml) after 12 and 11 passages in FLC-free medium, respectively. The MIC for one isolate grown in FLC (128 μg/ml) (128 R) reverted to 16 μg/ml but remained stable over 60 passages in FLC-free medium. Azole-resistant isolates revealed upregulation of two different multidrug efflux transporter genes: the major facilitators gene MDR1 and the ATP-binding cassette transporter CDR1. The development of FLC resistance in vitro correlated well with the results obtained in an experimental model of disseminated candidiasis. While FLC given at 10 mg/kg of body weight/day was effective in reducing the fungal burden of mice infected with the parent strain, the same dosing regimen was ineffective in mice infected with strain 128 R. Finally, the acquisition of in vitro FLC resistance in strain 128 R was related to a loss of virulence. The results of our study elucidate important characteristics and potential mechanisms of FLC resistance in C. tropicalis.Keywords
This publication has 53 references indexed in Scilit:
- In-vitro activity of five antifungal agents against uncommon clinical isolates of Candida spp.Journal of Antimicrobial Chemotherapy, 1999
- Fluconazole susceptibility and strain variation of Candida albicans isolates from HIV-infected patients with oropharyngeal candidosis [published erratum appears in J Antimicrob Chemother 1998 Sep;42(3):413]Journal of Antimicrobial Chemotherapy, 1998
- Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter geneMicrobiology, 1997
- Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida InfectionsClinical Infectious Diseases, 1997
- Detection and Significance of Fluconazole Resistance in Oropharyngeal Candidiasis in Human Immunodeficiency Virus-Infected PatientsThe Journal of Infectious Diseases, 1996
- Oral Azole Drugs as Systemic Antifungal TherapyNew England Journal of Medicine, 1994
- Characterization of an azole-resistant Candida glabrata isolateAntimicrobial Agents and Chemotherapy, 1992
- Increase inCandida kruseiInfection among Patients with Bone Marrow Transplantation and Neutropenia Treated Prophylactically with FluconazoleNew England Journal of Medicine, 1991
- Isolation of the Candida tropicalis gene for P450 lanosterol demethylase and its expression in Saccharomyces cerevisiaeBiochemical and Biophysical Research Communications, 1987
- The Lipid Composition of Azole-sensitive and Azole-resistant Strains of Candida albicansMicrobiology, 1986